<DOC>
	<DOCNO>NCT01884948</DOCNO>
	<brief_summary>To study efficacy safety intravenous Omegaven™ ( v . Placebo ) reduce postoperative morbidity mortality major liver resection .</brief_summary>
	<brief_title>Effects Omega-3 Fatty Acids Outcome After Major Liver Resection</brief_title>
	<detailed_description>With two single dos Omegaven ( pre- postoperatively ) aim reduce postoperative complication measure CCI ( Comprehensive Complication Index ) Clavien Dindo classification surgical complication . The study include adult ( 18 year ) patient require liver resection least 1 segment multiple wedge resection ( ≥3 ) .</detailed_description>
	<criteria>Inclusion criterion : Requiring liver resection least 1 segment multiple wedge resection ( =3 ) &gt; 18 year age No coagulopathy ( INR &lt; 1.2 , platelet &gt; 150'000 x10E3/µl ) Understands local language Exclusion criterion : Liver resection &lt; 1 segment Wedge resection ( &lt; 3 ) Liver cirrhosis Coagulopathy ( INR &gt; 1.2 , platelet &lt; 150'000 x10E3/µl ) Hypertriglyceridemia ( &gt; 5.0 mmol/l ) Hypersensitivity allergy Omegaven™ fish oil lipid emulsion Known allergy egg protein Pregnancy Nursing woman Renal failure ( estimate GFR &lt; 30 ml/min/1.73m2 ) Medication impair platelet aggregation Can understand local language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>least 1 segment</keyword>
	<keyword>multiple wedge resection ( ≥3 )</keyword>
</DOC>